Efficacy of multi-layered human iPS cell-derived cardiovascular cell sheets i a pacing-induced canine dilated cardiomyopathy model

Yu Shimoyama och colleagues testad IHJ-301, a multilayered human induced-pluripotent-stem-cell-derived cardiovascular cell sheet, i a pacing-induced canine dilated cardiomyopathy model. The construct combined cardiomyocytes, endothelial cells, och stromal cells. Five dogs received epicardial implantation och six received sham surgery. Four weeks later, the change i left-ventricular ejection fraction was 9.38 ± 1.47 percentage points with IHJ-301 versus 1.90 ± 0.34 with sham (p<0.05). Fractional shortening, stroke volume, och cardiac output also favored the cell-sheet group. The model was designed till maintain depressed cardiac function without mortality, which makes treatment readout easier. This is a useful large-animal bridge studie, but it is not a human prövning och it says nothing about longevity. The sample is very small. Follow-up was four weeks after implantation. The paper does not establish long-term engraftment, arrhythmia risk, tumor risk, durability, or clinical benefit i personer. The result supports continued translational testning of engineered cell sheets for heart failure. It does not justify clinic use or a generalized claim that iPSC therapies rejuvenate aging tissues.

We established a non-ischemic large-animal heart failure model that sustains depressed function for one month, enabling clear therapeutic readouts. IHJ-301 significantly improved multiple parameters of cardiac function, providing preclinical evidens that IHJ-301 could offer a promising therapeutic option for DCM.